Author Interviews, Cancer Research, Case Western, Cleveland Clinic, Mental Health Research / 25.04.2013

MedicalResearch.com: eInterview with Siran M. Koroukian, Ph.D. Population Health and Outcomes Research Core, Clinical & Translational Science Collaborative Associate Professor Department of Epidemiology and Biostatistics School of Medicine Case Western Reserve University Cleveland, OH 44106-7281 MedicalResearch.com: What are the main findings of the study? Dr. Koroukian: Among individuals who died of cancer, those with mental illness (MI) died an average of 10 years earlier than those without MI. Overall, there was excess mortality from cancer associated with having mental illness in all the race/sex strata: SMR, 2.16 (95% CI, 1.85-2.50) for black men; 2.63 (2.31-2.98) for black women; 3.89 (3.61-4.19) for nonblack men; and 3.34 (3.13-3.57) for nonblack women. We note statistically significant higher SMRs for every anatomic cancer site in nonblack men and women and for most cancer sites in black men and women.
Author Interviews, Cancer Research, Chemotherapy, Hormone Therapy / 23.04.2013

MedicalResearch.com eInterview with Andrew Weickhardt, MBBS, DMedSc, FRACP MedicalResearch.com: What are the main findings of the study? Dr. Weickhardt: The study was hoping to confirm our earlier published observation that crizotinib use led to low testosterone in male patients. The earlier study was based on our observation of symptoms of low testosterone in some patients treated with the drug, and had suggested strongly that crizotinib led to rapid decrease in testosterone levels, however this was based only on a single center's patients, and only 19 patients. We hoped to do this by surveying a larger population of crizotinib treated patients across multiple institutions. We serially measured several relevant hormones.
Author Interviews, Cancer Research / 12.04.2013

MedicalResearch.com eInterview with Vincent Yi-Fong Su MD Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan MedicalResearch.com: What are the main findings of the study? Answer: Amiodarone, one of the most widely used medications to treat arrhythmias may increase the risk of developing cancer, especially in men and people exposed to high amounts of the drug. That is the conclusion of a new retrospective study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. Patients who were male or who received high cumulative daily doses of amiodarone within the first year had an increased risk of developing cancer. Those with both factors were 46 percent more likely to develop cancer than those with neither factor.
Author Interviews, Breast Cancer, Genetic Research, PNAS / 03.04.2013

MedicalResearch.com eInterview with Dr. Mathieu Lupien PhD Dr. Mathieu Lupien PhD Princess Margaret Cancer Centre, University Health Network Ontario Cancer Institute (OCI) Assistant Professor Department of Medical Biophysics University of Toronto Princess Margaret Cancer Centre, University Health Network Ontario Cancer Institute (OCI) Assistant Professor Department of Medical Biophysics University of Toronto MedicalResearch.com: What are the main findings of the study? Dr. Lupien: Approximately 50% of breast cancer patients fail to respond to the standard of care based on endocrine (hormonal) therapy. Our research identifies a mechanism that accounts for this resistance. Drugs against this mechanism are already tested for other diseases. Hence, our discovery should rapidly help reposition these drugs against endocrine therapy resistant breast cancer.
Author Interviews, Cancer Research, PNAS / 02.04.2013

MedicalResearch.com Author Interview: Prof. Eytan Domany Department of Physics of Complex Systems and Department of Biological Regulation, Weizmann Institute of Science, Rehovot, 76100, IsraelDepartment of Physics of Complex Systems and Department of Biological Regulation, Weizmann Institute of Science, Rehovot, 76100, Israel MedicalResearch.com: What are the main findings of the study? Prof. Domany: The findings are two-fold: methodological and clinical.  A novel method was introduced for personalized analysis of cancer, and was applied on large colon cancer and glioblastoma datasets. The method uses high throughput (gene expression) data to infer a pathway deregulation score (PDS) for individual tumors, for hundreds of pathways and biological processes. The method is knowledge-based in that it uses well known information about the assignment of genes to biologically relevant pathways. No detailed knowledge of the underlying networks of interactions and activations is necessary. Each tumor is represented by a few hundred of these PDSs, and further analysis uses this representation.
Author Interviews, Cancer Research, Smoking, University of Pennsylvania / 01.04.2013

MedicalResearch.com Author Interview: Dr. Steven A. Branstetter, PhD The Pennsylvania State University, 315 E. HHD, University Park, PA 16810.Dr. Steven A. Branstetter, PhD The Pennsylvania State University, 315 E. HHD, University Park, PA 16810. MedicalResearch.com: What are the main findings of the study? Dr. Branstetter: This study demonstrated that the time to the first cigarette of the day after waking is associated with increased levels of a NNAL, a metabolite of a powerful tobacco-specific carcinogen, NNK -- even after controlling for the total number of cigarettes smoked per day. For years, the time to the first cigarette of the day after waking was one of several questions assessing nicotine dependence on the Fagerstrom Test for Nicotine Dependence (FTND), the gold standard questionnaire int he field. Over time, it was found that much of the predictive validity of the FTND was due to the time to first cigarette item. Researchers have found that single time to first cigarette item was highly correlated with other measures of nicotine dependence, and was predictive of more difficulty quitting smoking and increased intake of nicotine. Our current study demonstrates that this behavioral measure, is predictive of exposure to the cancer-causing components of cigarettes, regardless of the total number of cigarettes smoked per day. The results suggest that researchers, clinicians and smokers can assess the level of nicotine dependence and potential cancer risk by looking at the time to the first cigarette of the day after waking.
Cancer Research / 30.03.2013

Janet S. de Moor, PhD, MPH Program Director, Office of Cancer Survivorship Division of Cancer Control and Population Sciences National Cancer Institute/National Institutes of Health Bethesda, MD 20891-8336MedicalResearch.com Interview with Janet S. de Moor, PhD, MPH Program Director, Office of Cancer Survivorship Division of Cancer Control and Population Sciences National Cancer Institute/National Institutes of Health Bethesda, MD 20891-8336 MedicalResearch.com: What are the main findings of the study?  Dr. de Moor: The number of people who have been diagnosed with cancer during their lifetime has been steadily increasing.  As of January 1, 2012, approximately 13.7 million cancer survivors were living in the United States with projected prevalence to approach 18 million by 2022.  Women with breast cancer and men with prostate cancer represent the two largest groups of cancer survivors, accounting for 22% and 20% of the population respectively.  Sixty-four percent of cancer survivors have survived 5 years or more; 40% have survived 10 years or more; and 15% have survived 20 years or more after diagnosis.  Over the next decade, the number of people who have lived 5 years or more after their cancer diagnosis is projected to increase approximately 37% to 11.9 million.
Author Interviews, Breast Cancer, Cancer Research, Depression, Mental Health Research / 28.03.2013

MedicalResearch.com Interview with Mylin A. Torres, M.D. Assistant Professor Department of Radiation Oncology Emory University School of Medicine Atlanta, GA 30322 MedicalResearch.com: What are the main findings of the study?  Dr. Torres: Radiation treatment for breast cancer is not associated with increased depressive symptoms, but of disease and treatment-related factors, prior chemotherapy treatment is a significant predictor of depression before and after radiation treatment.  Prior chemotherapy treatment was associated with inflammatory mediators, including nuclear factor-kappa B DNA binding, soluble tumor necrosis factor-alpha receptor 2, and interleukin-6, which predicted for depressive symptoms after radiation on univariate analysis.
Author Interviews, Prostate Cancer, University of Pennsylvania / 28.03.2013

MEDICALRESEARCH.COM INTERVIEW WITH Charnita Zeigler-Johnson, Ph.D., M.P.H. Research Assistant Professor CCEB University of Pennsylvania MEDICALRESEARCH.COM: What are the main findings of the study? Dr. Zeigler-Johnson: The main findings of the study are:
  • Younger African-American men diagnosed with advanced prostate cancer at an early age (under the age of 60) are more likely to have had a personal history of early-onset baldness (baldness by age 30.)
  • For older patients, this is not necessarily the case, and future studies will need to focus on which factors place men in this age group at risk for prostate cancer.
Author Interviews, Duke, Genetic Research, Leukemia, MD Anderson, UT Southwestern / 23.03.2013

MedicalResearch.com Author Interview: Jun J. Yang, Ph.D. Assistant Member Dept. of Pharm. Sci. St. Jude Children's Research Hospital 262 Danny Thomas Pl., MS313 Memphis, TN 38105 MedicalResearch.com: What are the main findings of the study? Dr. Yang: We performed a comprehensive survey of inherited genetic variations for their contribution to the susceptibility of acute lymphoblastic leukemia (ALL), the most common cancer in children. This is by far the largest study of its kind (in terms of the number of subjects involved), and also the first one to include multi-ethnic populations. We identified 4 genomic loci related to the predisposition to ALL, 2 of which contributed to racial differences in the incidence of ALL.  This study provided unequivocal evidence for inherited susceptibility of childhood ALL and pointed to novel biology of the pathogenesis of this disease.
Author Interviews, Biomarkers, Cancer Research / 20.03.2013

MedicalResearch.com Interview with :Stig E. Bojesen Staff specialist, MD, PhD, DMSci Dept. of Clinical Biochemistry, Copenhagen University Hospital Herlev Hospital DK-2730 Herlev DenmarMedicalResearch.com Interview with Stig E. Bojesen Staff specialist, MD, PhD, DMSci Dept. of Clinical Biochemistry, Copenhagen University Hospital Herlev Hospital  DK-2730 Herlev  Denmark MedicalResearch.com: What are the main findings of the study?

Dr. Bojesen: The most interesting findings were the increased risk of early death after cancer by decreasing telomere length – measured even before the cancer disease surfaced in the individual. This association was present even after adjusting for all known markers of adverse prognosis. We did not expect this, but it has important implications for how we might apply this marker in the management of cancer patients. The second - and also important and unexpected finding - was the overall lack of association with risk of cancer, after adjustment for the most common ordinary risk factors like age, gender, smoking and so on. This was in contrast to former meta-analyses and many other smaller studies suggesting increased cancer risk with decreasing telomere length. We could reject this hypothesis with considerable statistical power.
Author Interviews, Cancer Research, Cost of Health Care, JNCI / 15.03.2013

Gabriel Brooks MD Fellow, Medical Oncology Dana-Farber Cancer InstituteMedicalResearch.com Interview with Gabriel Brooks MD Fellow, Medical Oncology Dana-Farber Cancer Institute MedicalResearch.com: What are the main findings of the study? Dr. Brooks: First, we found that there is substantial regional variation in Medicare spending for patients with advanced cancer.  For patients with a new diagnosis of advanced stage cancer, spending in the six months following diagnosis varied by 32% between regions in the highest and lowest quintiles of spending.  And for patients who died from cancer, spending in the last six months of life varied by 41% between the highest and lowest spending regions. Second, we tested the association between area-level spending and survival from the time of advanced cancer diagnosis.  We found that there was no consistent association between increasing spending and survival for any of the five cancer sites included in our study (non-small cell lung cancer, colorectal cancer, pancreas cancer, breast cancer and prostate cancer).
Author Interviews, Cancer Research, JNCI, Lung Cancer, NEJM / 08.03.2013

Dr. Martin C. Tammemägi Professor (Epidemiology) Brock University Department of Community Health Sciences Walker Complex – Academic South, Room 306 St. Catharines, Ontario, Canada L2S 3A1Medical Research.com Author Interview: Dr. Martin C. Tammemägi Professor (Epidemiology) Brock University Department of Community Health Sciences St. Catharines, Ontario, Canada L2S 3A1 Medical Research.com What are the main findings of the study?  Dr. Tammemägi: Our study accomplished three things: 1. We presented an updated Lung Cancer Risk Prediction Model, which compared to our previously JNCI-published model, incorporates more predictors but is simpler to use because we changed the way we modeled nonlinear effects. 2. We demonstrated that using the Lung Cancer Risk Prediction Model to select individuals for lung cancer screening was much more effective than using the National Lung Screening Trial (NLST) enrolment criteria.  41.3% fewer lung cancers were missed.  Sensitivity and positive predictive value of identifying individuals who develop lung cancer were significantly improved.  Shortly after our NEJM paper was published, Ma et al published in CANCER their findings that 8.6 million Americans are NLST-criteria positive and if they were CT screened under ideal conditions 12,000 lung cancer deaths would be averted.  Our NEJM article findings indicate that an additional 2,764 lives would be saved if the selection criteria had enrolled 8.6 million individuals for screening based on highest risk by our Lung Cancer Risk Prediction Model. 3. Importantly, using NLST data we demonstrated that the beneficial effect of CT screening did not vary by model predicted lung cancer risk.